SCHEMBL845933

SCHEMBL845933

COc1cccc(N)c1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.64
ALDH1A1 P00352 2/20 0.64
TP53 P04637 2/20 0.64
LMNA P02545 2/20 0.64
MAPT P10636 2/20 0.64
CYP3A4 P08684 1/20 0.64
HPGD P15428 1/20 0.64
ALOX15 P16050 1/20 0.64
ALOX12 P18054 1/20 0.64
MAPK1 P28482 1/20 0.64
HSD17B10 Q99714 1/20 0.64
ADRA2B P18089 1/20 0.60
PTGS1 P23219 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
TLR2 O60603 1/20 0.52
ERN1 O75460 1/20 0.52
TLR1 Q15399 1/20 0.52
TLR6 Q9Y2C9 1/20 0.52
IDO1 P14902 2/20 0.52
CA1 P00915 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4903925 0.98 ALDH1A1 (0.61) KDM4EALDH1A1TP53LMNAMAPT
Syringol SCHEMBL156388 0.83 KDM4E (0.80) KDM4EALDH1A1TP53LMNAMAPT
SCHEMBL565066 0.81 MMP2 (0.45) KDM4EALDH1A1TP53LMNAMAPT
Syringol SCHEMBL7610366 0.80 KDM4E (0.76) KDM4EALDH1A1TP53LMNAMAPT
Syringol SCHEMBL6049240 0.80 KDM4E (0.76) KDM4EALDH1A1TP53LMNAMAPT
Syringol SCHEMBL8986496 0.80 KDM4E (0.76) KDM4EALDH1A1TP53LMNAMAPT
SCHEMBL28424963 0.79 MMP2 (0.43) KDM4EALDH1A1TP53LMNAMAPT
3-Methoxycatechol SCHEMBL29477155 0.78 TP53 (1.00) KDM4EALDH1A1TP53LMNAMAPT
3-Methoxycatechol SCHEMBL67332 0.78 TP53 (1.00) KDM4EALDH1A1TP53LMNAMAPT
SCHEMBL3081933 0.78 ALDH1A1 (0.41) KDM4EALDH1A1TP53LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017116272-A1 METHOD FOR PREPARING TERTIARY AMINES COMPRISING ETHYNYLBENZYL SUBSTITUENTS PUBLIC JOINT STOCK COMPANY "SIBUR HOLDING" (RU) 2017-07-06 WO claimed
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. 2025-05-22 US disclosed
WO-2025096856-A1 COVALENT CEREBLON LIGANDS C4 THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 EP disclosed
CN-119730846-A Kinase modulators and methods of use thereof 神经元23公司 2025-03-28 CN disclosed
EP-4524139-A1 IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE Shanghai Simr Biotechnology Co., Ltd. (CN) 2025-03-19 EP disclosed
WO-2023244788-A9 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-09-12 WO disclosed
EP-4359381-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-05-01 EP disclosed
CN-117858865-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 CN disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
CN-1023324-C Method of preventing polymer-scale formation SHINETSU CHEMICAL CO (JP) 1993-12-29 CN disclosed
CN-1020610-C PROCESS FOR PREPARATION OF SUBSTITUTED BENZOXAZINE RIFAMYCIN KANEGAFUCHI CHEMICAL IND (JP) 1993-05-12 CN disclosed
US-5128428-A Polymer of a maleimide compound and an aminovinylbenzyl compound SHOWA HIGHPOLYMER CO., LTD. (JP) 1992-07-07 US disclosed
US-4965261-A Substituted benzoxazinorifamycin derivative and antibacterial agent containing the same KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1990-10-23 US disclosed
US-4933399-A COATING INSIDE OF VESSEL WITH A CATIONIC DYE, DRYING, COATING WITH AN ANIONIC OR AMPHOTERIC POLYMER OR A HYDROXYL-CONTAINING COMPOUND IN A SOLVENT SHIN-ETSU CHEMICAL CO., LTD. (JP) 1990-06-12 US disclosed
CN-1036576-A Benzoxazine rifomycin that replaces and preparation method thereof and the antiseptic-germicide that contains this rifomycin KANEGAFUCHI CHEMICAL IND (JP) 1989-10-25 CN disclosed
EP-0333176-A2 Substituted benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1989-09-20 EP disclosed
CN-1035118-A A kind of method that forms polymer-scale that stops SHINETSU CHEMICAL CO (JP) 1989-08-30 CN disclosed
EP-0320227-A2 Method of preventing polymer-scale formation Shin-Etsu Chemical Co., Ltd. (JP) 1989-06-14 EP disclosed
US-4207318-A ANTIALLERGIC ACTIVITY, BRONCHODILATOR ROUSSEL UCLAF (FR) 1980-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC KDM4E 623/4885ALDH1A1 4185/4885TP53 378/4885
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, JAK1, JAK3 KDM4E 623/4885ALDH1A1 4807/4885TP53 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.